Abstract
Few selective cyclooxygenase-1 (COX-1) inhibitors have been described up to now, although recent studies underlined the involvement of COX-1 in the carcinogenesis, pathogenesis of neuroinflammation, cardiovascular diseases and pain. Among the known COX-1 inhibitors none proved to be a good drug candidate, with the exception of mofezolac, that is clinically used as an analgesic drug. New selective inhibitors were very often discovered as a minor achievement during SAR investigations to discover selective COX-2 inhibitors (COXIBs). After a recognition of the new COX-1 inhibitors synthesized in the last five years, it was attempted to draw, for each chemical class, a structure which might highlight the determinant molecular features able to switch the selectivity towards the COX-1 isoform. Overall, this review could constitute a tool to a better design of novel selective COX-1 inhibitors, to be used in a disease theranostic approach targeting COX-1.
Keywords: Cyclooxygenase (COX)-1, COX-2, structure-activity relationship(SAR), diarylheterocycles, benzanilides, arylpropanoic acids, stilbenes, NSAIDs.
Current Medicinal Chemistry
Title:Update on SAR Studies Toward New COX-1 Selective Inhibitors
Volume: 22 Issue: 37
Author(s): Paola Vitale, Antonio Scilimati and Maria Grazia Perrone
Affiliation:
Keywords: Cyclooxygenase (COX)-1, COX-2, structure-activity relationship(SAR), diarylheterocycles, benzanilides, arylpropanoic acids, stilbenes, NSAIDs.
Abstract: Few selective cyclooxygenase-1 (COX-1) inhibitors have been described up to now, although recent studies underlined the involvement of COX-1 in the carcinogenesis, pathogenesis of neuroinflammation, cardiovascular diseases and pain. Among the known COX-1 inhibitors none proved to be a good drug candidate, with the exception of mofezolac, that is clinically used as an analgesic drug. New selective inhibitors were very often discovered as a minor achievement during SAR investigations to discover selective COX-2 inhibitors (COXIBs). After a recognition of the new COX-1 inhibitors synthesized in the last five years, it was attempted to draw, for each chemical class, a structure which might highlight the determinant molecular features able to switch the selectivity towards the COX-1 isoform. Overall, this review could constitute a tool to a better design of novel selective COX-1 inhibitors, to be used in a disease theranostic approach targeting COX-1.
Export Options
About this article
Cite this article as:
Vitale Paola, Scilimati Antonio and Perrone Grazia Maria, Update on SAR Studies Toward New COX-1 Selective Inhibitors, Current Medicinal Chemistry 2015; 22 (37) . https://dx.doi.org/10.2174/0929867322666151029104717
DOI https://dx.doi.org/10.2174/0929867322666151029104717 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Searching for Novel Janus Kinase-2 Inhibitors Using a Combination of Pharmacophore Modeling, 3D-QSAR Studies and Virtual Screening
Mini-Reviews in Medicinal Chemistry Extracellular Superoxide and the Growth of Pancreatic Carcinoma
Current Cancer Therapy Reviews Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Cardiovascular Drugs and Bone
Current Drug Safety Recent Applications of RNAi in Mammalian Systems
Current Pharmaceutical Biotechnology Molecular Therapeutics of HBV
Current Gene Therapy Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Physiology of Immune System: Regulation of Stem Cell Survival
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Anti-Platelet Therapy and Aspirin Resistance – Clinically and Chemically Relevant?
Current Medicinal Chemistry Are Chemically Reactive Metabolites Responsible for Adverse Reactions to Drugs?
Current Drug Metabolism Sample Treatment in Organic Compound Determination: A Green Chemistry Perspective
Current Green Chemistry Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
Current Drug Metabolism Aqueous Extracts of Selected Potentilla Species Modulate Biological Activity of Human Normal Colon Cells
Current Drug Targets Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Anti-inflammatory and Antioxidant Effects of <i>Lotus corniculatus</i> on Paracetamol-induced Hepatitis in Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design A Review on Designing Poly (Lactic-co-glycolic Acid) Nanoparticles as Drug Delivery Systems
Pharmaceutical Nanotechnology The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery